Ultraflex Powers Mayo Clinic’s First Hyperthermia Cancer Research

The system is part of the Sarah Nanotechnology System, an investigational platform developed by New Phase Ltd. The Mayo Clinic study is an early feasibility clinical trial evaluating safety, dosing, and initial performance. No treatment efficacy claims are made.

Download diagram (PNG, 4800×2160)

Mayo Clinic completed installation of the machine within its Radiation Oncology Department in November 2025, and the first U.S. patient received treatment as part of the clinical trial in December 2025. The collaboration was announced publicly by Mayo Clinic earlier this year. Full details are available on the Mayo Clinic News Network and on the New Phase Mayo Clinic program page.

How the Technology Works

The Sarah Nanotechnology System uses proprietary Sarah Nanoparticles (SaNP) — encapsulated, superparamagnetic iron-oxide particles — administered intravenously. Due to their size and surface properties, the nanoparticles are intended to preferentially accumulate in tumor tissue. Once concentrated inside the tumor, the Ultraflex-built Electromagnetic Induction System (EIS) generates a precisely controlled alternating magnetic field that activates those nanoparticles, converting electromagnetic energy into targeted heat with the goal of damaging cancer cells while limiting heating of surrounding healthy tissue. A special coating on the nanoparticles limits the maximum temperature to approximately 50 °C.

The alternating magnetic field is non-ionizing, meaning it does not remove electrons from atoms the way X-rays can. Each tumor effectively becomes its own induction target — a different engineering approach to localized tumor heating for advanced, metastatic solid tumors.

Ultraflex’s Contribution

Ultraflex’s engineering team designed and manufactured the core hardware of the platform, including:

• The precision radiofrequency (RF) power source
• A custom-engineered electromagnetic induction coil
• A closed-loop control system for field regulation and safety
• An automated patient table integrated with the treatment workflow

Each component was engineered, assembled, and validated at Ultraflex to meet the demanding safety, precision, and reliability standards required for a clinical research environment. The project extends Ultraflex’s NanoSeries platform — already in use at universities, research institutes, and corporate laboratories worldwide — into a clinical-grade application.

https://ultraflexpower.com/

Clinical Trial Overview

The open-label, dose-escalation early feasibility study at Mayo Clinic is evaluating the safety, dosing, and initial performance of the Sarah Nanotechnology System in patients with metastatic solid tumors in any body area except the brain. Multiple tumors can be treated simultaneously, including deep-seated tumors that are difficult to address with existing hyperthermia approaches.

New Phase reports that early experience has shown an excellent safety profile with only minor, transient side effects; the Mayo Clinic trial remains ongoing.

From Industrial Induction to Medical Innovation

For more than 25 years, Ultraflex Power Technologies has designed and manufactured digitally controlled induction heating systems for brazing, heat treating, melting, casting, and precision research applications. The Mayo Clinic deployment represents a deliberate extension of that engineering capability into medicine — a frontier where the precision of induction physics can translate directly into patient benefit.

This milestone shows how Ultraflex is extending induction heating into new medical frontiers, applying precise electromagnetic field control to support nanoparticle hyperthermia research.